113 related articles for article (PubMed ID: 11162500)
21. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex.
Nourani A; Doyon Y; Utley RT; Allard S; Lane WS; Côté J
Mol Cell Biol; 2001 Nov; 21(22):7629-40. PubMed ID: 11604499
[TBL] [Abstract][Full Text] [Related]
22. The DNA-binding and transcription-activation abilities of p53 are necessary but not sufficient for its antiproliferation function.
Zhang W; Randhawa GS; Guo XY; Deisseroth AB
Cell Growth Differ; 1994 Jul; 5(7):705-10. PubMed ID: 7947385
[TBL] [Abstract][Full Text] [Related]
23. Regulation of specific DNA binding by p53: evidence for a role for O-glycosylation and charged residues at the carboxy-terminus.
Shaw P; Freeman J; Bovey R; Iggo R
Oncogene; 1996 Feb; 12(4):921-30. PubMed ID: 8632915
[TBL] [Abstract][Full Text] [Related]
24. Physical and functional interactions between members of the tumour suppressor p53 and the Sp families of transcription factors: importance for the regulation of genes involved in cell-cycle arrest and apoptosis.
Koutsodontis G; Vasilaki E; Chou WC; Papakosta P; Kardassis D
Biochem J; 2005 Jul; 389(Pt 2):443-55. PubMed ID: 15790310
[TBL] [Abstract][Full Text] [Related]
25. Identification of the regulatory region required for ubiquitination of the cyclin kinase inhibitor, p21.
Fukuchi K; Hagiwara T; Nakamura K; Ichimura S; Tatsumi K; Gomi K
Biochem Biophys Res Commun; 2002 Apr; 293(1):120-5. PubMed ID: 12054572
[TBL] [Abstract][Full Text] [Related]
26. Regulation of the specific DNA binding activity of Xenopus laevis p53: evidence for conserved regulation through the carboxy-terminus of the protein.
Bessard AC; Garay E; Lacronique V; Legros Y; Demarquay C; Houque A; Portefaix JM; Granier C; Soussi T
Oncogene; 1998 Feb; 16(7):883-90. PubMed ID: 9484779
[TBL] [Abstract][Full Text] [Related]
27. Mutant p53 forms a complex with Sp1 on HIV-LTR DNA.
Chicas A; Molina P; Bargonetti J
Biochem Biophys Res Commun; 2000 Dec; 279(2):383-90. PubMed ID: 11118296
[TBL] [Abstract][Full Text] [Related]
28. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
29. Association of JNK1 with p21waf1 and p53: modulation of JNK1 activity.
Xue Y; Ramaswamy NT; Hong X; Pelling JC
Mol Carcinog; 2003 Jan; 36(1):38-44. PubMed ID: 12503078
[TBL] [Abstract][Full Text] [Related]
30. p53 is a NF-Y- and p21-independent, Sp1-dependent repressor of cyclin B1 transcription.
Innocente SA; Lee JM
FEBS Lett; 2005 Feb; 579(5):1001-7. PubMed ID: 15710382
[TBL] [Abstract][Full Text] [Related]
31. The effect of potent iron chelators on the regulation of p53: examination of the expression, localization and DNA-binding activity of p53 and the transactivation of WAF1.
Liang SX; Richardson DR
Carcinogenesis; 2003 Oct; 24(10):1601-14. PubMed ID: 12869419
[TBL] [Abstract][Full Text] [Related]
32. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.
Seoane J; Le HV; Massagué J
Nature; 2002 Oct; 419(6908):729-34. PubMed ID: 12384701
[TBL] [Abstract][Full Text] [Related]
33. Analysis of p53 quaternary structure in relation to sequence-specific DNA binding.
Hainaut P; Hall A; Milner J
Oncogene; 1994 Jan; 9(1):299-303. PubMed ID: 8302593
[TBL] [Abstract][Full Text] [Related]
34. Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments.
Caron de Fromentel C; Gruel N; Venot C; Debussche L; Conseiller E; Dureuil C; Teillaud JL; Tocque B; Bracco L
Oncogene; 1999 Jan; 18(2):551-7. PubMed ID: 9927212
[TBL] [Abstract][Full Text] [Related]
35. Wild-type, but not mutant-type, p53 enhances nuclear accumulation of the NS3 protein of hepatitis C virus.
Ishido S; Muramatsu S; Fujita T; Iwanaga Y; Tong WY; Katayama Y; Itoh M; Hotta H
Biochem Biophys Res Commun; 1997 Jan; 230(2):431-6. PubMed ID: 9016797
[TBL] [Abstract][Full Text] [Related]
36. Identification of p53 target genes through immune selection of genomic DNA: the cyclin G gene contains two distinct p53 binding sites.
Zauberman A; Lupo A; Oren M
Oncogene; 1995 Jun; 10(12):2361-6. PubMed ID: 7784084
[TBL] [Abstract][Full Text] [Related]
37. Xenopus laevis p53 protein: sequence-specific DNA binding, transcriptional regulation and oligomerization are evolutionarily conserved.
Wang Y; Farmer G; Soussi T; Prives C
Oncogene; 1995 Feb; 10(4):779-84. PubMed ID: 7862457
[TBL] [Abstract][Full Text] [Related]
38. In vitro analysis of the dominant negative effect of p53 mutants.
Chène P
J Mol Biol; 1998 Aug; 281(2):205-9. PubMed ID: 9698540
[TBL] [Abstract][Full Text] [Related]
39. Mutations at position 277 modify the DNA-binding specificity of human p53 in vitro.
Chène P
Biochem Biophys Res Commun; 1999 Sep; 263(1):1-5. PubMed ID: 10486243
[TBL] [Abstract][Full Text] [Related]
40. Identification of an allosteric binding site on the transcription factor p53 using a phage-displayed peptide library.
Ravera MW; Cárcamo J; Brissette R; Alam-Moghé A; Dedova O; Cheng W; Hsiao KC; Klebanov D; Shen H; Tang P; Blume A; Mandecki W
Oncogene; 1998 Apr; 16(15):1993-9. PubMed ID: 9591783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
